Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
Phillip J MeaseAtul A DeodharDésirée Mfm van der HeijdeFrank BehrensAlan J KivitzJeffrey NealJonghyeon KimShalabh SinghalMiroslawa NowakSubhashis BanerjeePublished in: Annals of the rheumatic diseases (2022)
NCT03881059.